Skip to main content

Biogen Fumarate revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Fumarate revenue at Biogen came to $274.0M for the quarter to 30 Sep 2026, down 28.4% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$400.7MDec 2023$381.8MMar 2024$418.0MJun 2024$390.9MSep 2024$404.4MDec 2024$344.9MMar 2025$405.9MJun 2025$382.8MSep 2025$292.9MDec 2025$288.5MMar 2026$287.4MJun 2026$274.0MSep 2026
Biogen Fumarate revenue, every reported period
Period endingFumarate revenueChange on a yearFiled
30 Sep 2026$274.0Mdown 28.4%28 Oct 2026
30 Jun 2026$287.4Mdown 29.2%29 Jul 2026
31 Mar 2026$288.5Mdown 16.4%29 Apr 2026
31 Dec 2025$292.9Mdown 27.6%6 Feb 2026
30 Sep 2025$382.8Mdown 2.1%30 Oct 2025
30 Jun 2025$405.9Mdown 2.9%31 Jul 2025
31 Mar 2025$344.9Mdown 9.7%1 May 2025
31 Dec 2024$404.4Mup 0.9%12 Feb 2025
30 Sep 2024$390.9Mdown 3.5%30 Oct 2024
30 Jun 2024$418.0Mup 4.4%1 Aug 2024
31 Mar 2024$381.8Mdown 0.2%24 Apr 2024
31 Dec 2023$400.7Mdown 10.5%14 Feb 2024
30 Sep 2023$405.0Mdown 15.1%8 Nov 2023
30 Jun 2023$400.4Mdown 25.1%25 Jul 2023
31 Mar 2023$382.7Mdown 28.9%25 Apr 2023
31 Dec 2022$447.9Mdown 26.7%15 Feb 2023
30 Sep 2022$476.8Mdown 23.0%25 Oct 2022
30 Jun 2022$534.7Mdown 7.6%20 Jul 2022
31 Mar 2022$537.9Mdown 2.7%3 May 2022
31 Dec 2021$611.4Mdown 5.5%3 Feb 2022
30 Sep 2021$619.5Mdown 36.0%20 Oct 2021
30 Jun 2021$578.5Mdown 51.4%22 Jul 2021
31 Mar 2021$552.9Mdown 49.8%22 Apr 2021
31 Dec 2020$646.8M—3 Feb 2021
30 Sep 2020$967.5Mdown 13.8%21 Oct 2020
30 Jun 2020$1.2Bup 3.5%22 Jul 2020
31 Mar 2020$1.1B—23 Apr 2020
30 Sep 2019$1.1B—22 Oct 2019
30 Jun 2019$1.2B—24 Jul 2019

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.